SCHEMBL23588293

SCHEMBL23588293

CCOP(=O)(OCC)C(Cc1nc(-c2ccc(Br)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SIRT2 Q8IXJ6 3/20 0.39
TP53 P04637 5/20 0.39
MITF O75030 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
THRB P10828 1/20 0.38
TSHR P16473 5/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2C19 P33261 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 3/20 0.38
ALOX15 P16050 2/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25802128 0.91 LMNA (0.39) HTTMEN1KMT2ATDP1L3MBTL1
SCHEMBL25807564 0.90 TP53 (0.39) HTTMEN1KMT2ATDP1SIRT2
SCHEMBL25804401 0.90 TSHR (0.47) HTTMEN1KMT2ASIRT2TP53
SCHEMBL23588294 0.90 TP53 (0.39) HTTMEN1KMT2ATDP1SIRT2
SCHEMBL23588138 0.88 TP53 (0.37) HTTMEN1KMT2ASIRT2TP53
SCHEMBL23578576 0.87 RAB9A (0.40) KMT2ATP53MITFNCOA3SMN1; SMN2
SCHEMBL25804667 0.87 SPHK1 (0.43) SIRT2TP53MITFNCOA3SMN1; SMN2
SCHEMBL23588079 0.87 ACACB (0.46) SIRT2TP53MITFNCOA3SMN1; SMN2
SCHEMBL23578218 0.86 SPHK1 (0.47)
SCHEMBL23588176 0.85 S1PR4 (0.40) TP53MITFNCOA3SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 CN disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 HTT 4546/4885MEN1 4504/4885KMT2A 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.